Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients

Esteban Martínez*, Juan A. Arnaiz, Daniel Podzamczer, David Dalmau, Esteban Ribera, Pere Domingo, Hernando Knobel, Maria Leyes, Enric Pedrol, Luís Force, Elisa De Lazzari, José M. Gatell

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

35 Citations (Scopus)

Abstract

Patients with sustained virological suppression on protease inhibitor (PI)-based therapy were randomly assigned to switch the PI to nevirapine (n = 155), efavirenz (n = 156), or abacavir (n = 149) and were followed for at least 3 years regardless of the discontinuation of assigned therapy. There was a higher probability of maintaining virological suppression after 3 years of follow-up with nevirapine or efavirenz than with abacavir. In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation.

Original languageAmerican English
Pages (from-to)367-369
Number of pages3
JournalAIDS
Volume21
Issue number3
DOIs
Publication statusPublished - Jan 2007

Fingerprint Dive into the research topics of 'Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients'. Together they form a unique fingerprint.

Cite this